denovoSkin
Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0denovoSkin project word cloud
Explore the words cloud of the denovoSkin project. It provides you a very rough idea of what is the project "denovoSkin" about.
Project "denovoSkin" data sheet
The following table provides information about the project.
| Coordinator |
CUTISS AG
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Project website | http://cutiss.swiss/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing) 2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-01-01 to 2018-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CUTISS AG | CH (ZURICH) | coordinator | 50˙000.00 |
Map
Project objective
Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore skin function. Standard of care, skin autografting, very often leaves these patients with scars. Scars are permanent and disfiguring, and can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life, along with the economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real clinical issue. denovoSkin™ is a patented, personalized, bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin is expected to minimally scar after transplantation. Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings in terms of costs. denovoSkin™ is granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. So far, more than €14M have been invested over the last 16 years of research into the development and the clinical testing of denovoSkin™. To have denovoSkin™ fully projected at a European and global level we need a further investment of €3.57M to set up a solid EU value chain able to meet the large demand expected during the commercialisation via developing the automation of manufacture. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of denovoSkin™ and its market uptake.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DENOVOSKIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DENOVOSKIN" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)
Gri3D (2018)
The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.
Read More